| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | voltage-gated monoatomic ion channel activity | 6.15e-05 | 182 | 24 | 4 | GO:0005244 | |
| GeneOntologyMolecularFunction | voltage-gated channel activity | 6.42e-05 | 184 | 24 | 4 | GO:0022832 | |
| GeneOntologyMolecularFunction | high voltage-gated calcium channel activity | 1.25e-04 | 14 | 24 | 2 | GO:0008331 | |
| GeneOntologyMolecularFunction | inorganic molecular entity transmembrane transporter activity | 2.20e-04 | 758 | 24 | 6 | GO:0015318 | |
| GeneOntologyMolecularFunction | monoatomic ion transmembrane transporter activity | 2.80e-04 | 793 | 24 | 6 | GO:0015075 | |
| GeneOntologyMolecularFunction | gated channel activity | 6.27e-04 | 334 | 24 | 4 | GO:0022836 | |
| GeneOntologyMolecularFunction | inorganic cation transmembrane transporter activity | 7.78e-04 | 627 | 24 | 5 | GO:0022890 | |
| GeneOntologyMolecularFunction | voltage-gated monoatomic cation channel activity | 7.78e-04 | 152 | 24 | 3 | GO:0022843 | |
| GeneOntologyMolecularFunction | monoatomic cation transmembrane transporter activity | 1.01e-03 | 664 | 24 | 5 | GO:0008324 | |
| GeneOntologyMolecularFunction | voltage-gated calcium channel activity | 1.39e-03 | 46 | 24 | 2 | GO:0005245 | |
| GeneOntologyMolecularFunction | monoatomic ion channel activity | 2.03e-03 | 459 | 24 | 4 | GO:0005216 | |
| GeneOntologyMolecularFunction | metal ion transmembrane transporter activity | 2.13e-03 | 465 | 24 | 4 | GO:0046873 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | 2.25e-03 | 1180 | 24 | 6 | GO:0022857 | |
| GeneOntologyMolecularFunction | channel activity | 3.30e-03 | 525 | 24 | 4 | GO:0015267 | |
| GeneOntologyMolecularFunction | passive transmembrane transporter activity | 3.33e-03 | 526 | 24 | 4 | GO:0022803 | |
| GeneOntologyMolecularFunction | transporter activity | 3.51e-03 | 1289 | 24 | 6 | GO:0005215 | |
| GeneOntologyMolecularFunction | monoatomic cation channel activity | 7.78e-03 | 343 | 24 | 3 | GO:0005261 | |
| GeneOntologyCellularComponent | asymmetric, glutamatergic, excitatory synapse | 3.43e-04 | 24 | 24 | 2 | GO:0098985 | |
| GeneOntologyCellularComponent | monoatomic ion channel complex | 8.40e-04 | 378 | 24 | 4 | GO:0034702 | |
| GeneOntologyCellularComponent | voltage-gated calcium channel complex | 1.27e-03 | 46 | 24 | 2 | GO:0005891 | |
| GeneOntologyCellularComponent | transmembrane transporter complex | 2.76e-03 | 523 | 24 | 4 | GO:1902495 | |
| GeneOntologyCellularComponent | calcium channel complex | 3.16e-03 | 73 | 24 | 2 | GO:0034704 | |
| GeneOntologyCellularComponent | dendritic shaft | 3.24e-03 | 74 | 24 | 2 | GO:0043198 | |
| GeneOntologyCellularComponent | transporter complex | 3.31e-03 | 550 | 24 | 4 | GO:1990351 | |
| HumanPheno | Abnormal circulating unsaturated fatty acid concentration | 9.65e-05 | 8 | 10 | 2 | HP:0011022 | |
| HumanPheno | Abnormal circulating eicosanoid concentration | 9.65e-05 | 8 | 10 | 2 | HP:0030361 | |
| Domain | CAC1F_C | 4.74e-06 | 3 | 24 | 2 | PF16885 | |
| Domain | CAC1F_C | 4.74e-06 | 3 | 24 | 2 | IPR031688 | |
| Domain | VDCC_L_a1su | 9.48e-06 | 4 | 24 | 2 | IPR005446 | |
| Domain | GPHH_dom | 3.31e-05 | 7 | 24 | 2 | IPR031649 | |
| Domain | VDCC_a1su_IQ | 3.31e-05 | 7 | 24 | 2 | IPR014873 | |
| Domain | Ca_chan_IQ | 3.31e-05 | 7 | 24 | 2 | SM01062 | |
| Domain | Ca_chan_IQ | 3.31e-05 | 7 | 24 | 2 | PF08763 | |
| Domain | GPHH | 3.31e-05 | 7 | 24 | 2 | PF16905 | |
| Domain | VDCCAlpha1 | 7.08e-05 | 10 | 24 | 2 | IPR002077 | |
| Domain | Channel_four-helix_dom | 2.42e-03 | 57 | 24 | 2 | IPR027359 | |
| Domain | - | 2.42e-03 | 57 | 24 | 2 | 1.20.120.350 | |
| Domain | Ion_trans_dom | 9.34e-03 | 114 | 24 | 2 | IPR005821 | |
| Domain | Ion_trans | 9.34e-03 | 114 | 24 | 2 | PF00520 | |
| Pathway | KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_VGCC_CA2_APOPTOTIC_PATHWAY | 2.30e-05 | 6 | 18 | 2 | M47762 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_VGCC_CA2_APOPTOTIC_PATHWAY_N01004 | 1.39e-04 | 14 | 18 | 2 | M47692 | |
| Pathway | KEGG_GNRH_SIGNALING_PATHWAY | 2.69e-04 | 101 | 18 | 3 | M1979 | |
| Pathway | KEGG_MEDICUS_REFERENCE_VGCC_CA2_APOPTOTIC_PATHWAY | 3.83e-04 | 23 | 18 | 2 | M47666 | |
| Pathway | KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION | 3.95e-04 | 115 | 18 | 3 | M9387 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_ENTRY_VOLTAGE_GATED_CA2_CHANNEL | 4.54e-04 | 25 | 18 | 2 | M47948 | |
| Pubmed | Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development. | 2.44e-06 | 139 | 24 | 4 | 16985003 | |
| Pubmed | 2.74e-06 | 4 | 24 | 2 | 20937870 | ||
| Pubmed | 9.56e-06 | 7 | 24 | 2 | 12900400 | ||
| Pubmed | 1.64e-05 | 9 | 24 | 2 | 16382099 | ||
| Pubmed | 2.50e-05 | 11 | 24 | 2 | 18809727 | ||
| Pubmed | 4.77e-05 | 15 | 24 | 2 | 24453333 | ||
| Pubmed | 4.77e-05 | 15 | 24 | 2 | 20188150 | ||
| Pubmed | Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development. | 3.16e-04 | 38 | 24 | 2 | 30786075 | |
| Pubmed | 4.34e-04 | 216 | 24 | 3 | 31519766 | ||
| Pubmed | The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival. | 4.58e-04 | 220 | 24 | 3 | 31822558 | |
| Pubmed | 5.77e-04 | 568 | 24 | 4 | 9110174 | ||
| Pubmed | A "double adaptor" method for improved shotgun library construction. | 6.00e-04 | 574 | 24 | 4 | 8619474 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr6q23 | 1.77e-03 | 119 | 24 | 2 | chr6q23 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr4q13 | 3.05e-03 | 157 | 24 | 2 | chr4q13 | |
| GeneFamily | Calcium voltage-gated channel subunits | 2.67e-04 | 26 | 17 | 2 | 253 | |
| ToppCell | TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Mucinous_Colon_Adenocarcinoma-7|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 2.85e-05 | 111 | 24 | 3 | 6a03fbeea8363a142c3c4d68e5aab106ce1bab31 | |
| ToppCell | Control-Epithelial_alveolar-Mes-Like|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.25e-05 | 116 | 24 | 3 | df7609503782d8d7e4f31ed2a626916e5474d5bc | |
| ToppCell | Control-Epithelial_alveolar-Mes-Like-Differentiating_AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.26e-05 | 127 | 24 | 3 | 556aaf88719c83f307fa50dfac151136ed05c8ad | |
| ToppCell | 343B-Epithelial_cells-Epithelial-H_(AT1)|343B / Donor, Lineage, Cell class and subclass (all cells) | 7.99e-05 | 157 | 24 | 3 | 70fd6c46db4250c7de5c4686a9500689402737f6 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-H_(AT1)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 7.99e-05 | 157 | 24 | 3 | dd08dc19d434e94a194076c462ee273c682abf55 | |
| ToppCell | 10x5'-bone_marrow-Mast|bone_marrow / Manually curated celltypes from each tissue | 8.30e-05 | 159 | 24 | 3 | c3d3570e83c5d25cc92fa3a7a8f0dc2f89a72913 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_12|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.07e-04 | 173 | 24 | 3 | a55f310c533432e9e26e400026a5b47245152976 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_12|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.07e-04 | 173 | 24 | 3 | 9c7386bf0a899882c733f0b4921a96afde032a7d | |
| ToppCell | CTRL-Lymphoid-pDC|Lymphoid / Disease state, Lineage and Cell class | 1.08e-04 | 174 | 24 | 3 | ff4315e9fad198cc323fc987deb8652da137cf98 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum_-18m-Mesenchymal-ependymal_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.20e-04 | 180 | 24 | 3 | 9ef79a7c60227e352ac166c7274adb31f585f5ca | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum_-18m-Mesenchymal-Ependyma|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.20e-04 | 180 | 24 | 3 | 729f0d7af573c7796d8e28e6eec3af2fc0bd33a2 | |
| ToppCell | 10x5'-bone_marrow-Mast-Mast_cell_lympho|bone_marrow / Manually curated celltypes from each tissue | 1.22e-04 | 181 | 24 | 3 | 56fa77ae31f3b7de6e441a439c33a11353b6573a | |
| ToppCell | COVID-19-kidney-Distal_Epi_Doublet_(PCT)|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.24e-04 | 182 | 24 | 3 | 9d67717a6e13bcb54c1297a3e4e3abf4e51628a3 | |
| ToppCell | hematopoetic_progenitors-CD34+_MEP_2|World / Lineage and Cell class | 1.24e-04 | 182 | 24 | 3 | a7e7aa10f14111a6c7ba22e0f1668dcaa124714d | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN4_thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.30e-04 | 185 | 24 | 3 | d50406a9a5b8d75110ba5985741aa2293950c543 | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN4_thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.30e-04 | 185 | 24 | 3 | a2cae8c657e4f4d121476798e424876f7e247973 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.32e-04 | 186 | 24 | 3 | e83718fabb057100835d3357df407f283d23fe16 | |
| ToppCell | hematopoetic_progenitors-CD34+_MEP_2|hematopoetic_progenitors / Lineage and Cell class | 1.43e-04 | 191 | 24 | 3 | 3b061dbc10918be7cbbd4453311d2c1ebf18c6b2 | |
| ToppCell | renal_cortex_nuclei|World / Celltypes from Cells and Nuclei per compartment and clinical group | 1.45e-04 | 192 | 24 | 3 | e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a | |
| Computational | Neighborhood of RAD54L | 3.05e-04 | 105 | 14 | 3 | MORF_RAD54L | |
| Drug | Niflumic Acid | 6.38e-06 | 4 | 24 | 2 | DB04552 | |
| Drug | Cinnarizine | 3.82e-05 | 9 | 24 | 2 | DB00568 | |
| Drug | Nimodipine | 3.82e-05 | 9 | 24 | 2 | DB00393 | |
| Drug | Mibefradil | 5.82e-05 | 11 | 24 | 2 | DB01388 | |
| Drug | N-cyclopentyl-N-cyclobutylformamide | 7.72e-05 | 79 | 24 | 3 | CID005287890 | |
| Drug | Verapamil | 1.27e-04 | 16 | 24 | 2 | DB00661 | |
| Drug | nitrendipine | 1.47e-04 | 98 | 24 | 3 | CID000004507 | |
| Disease | Timothy syndrome (implicated_via_orthology) | 3.80e-06 | 4 | 24 | 2 | DOID:0060173 (implicated_via_orthology) | |
| Disease | Autistic Disorder | 5.53e-05 | 261 | 24 | 4 | C0004352 | |
| Disease | Duchenne muscular dystrophy (implicated_via_orthology) | 3.93e-04 | 36 | 24 | 2 | DOID:11723 (implicated_via_orthology) | |
| Disease | FEV change measurement, response to bronchodilator | 1.02e-03 | 58 | 24 | 2 | EFO_0005921, GO_0097366 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| DPMAYGAMFPGFGGM | 271 | Q9NP70 | |
| DMKGEVYPFGIVGMA | 626 | O75534 | |
| GYMDFPKVGGMPFSV | 2521 | O75179 | |
| PKVGGMPFSVYGNAM | 2526 | O75179 | |
| MGKHVYIFGGMTPAG | 251 | Q7Z6M1 | |
| VMYDGIMAYGGPFFP | 716 | O60840 | |
| IMAYGGPFFPGMLVC | 721 | O60840 | |
| TAMKLGAGYPMGPFE | 246 | Q16836 | |
| MAPLSPGGKAFCMVY | 111 | Q9Y2U2 | |
| VGGMEYSPGMVYIAP | 1216 | Q9HCM2 | |
| GPKPVMVYIHGGSYM | 211 | Q8N2Q7 | |
| VMYDGIMAYGGPSFP | 711 | Q13936 | |
| IMAYGGPSFPGMLVC | 716 | Q13936 | |
| EKAYMKVMGGYDFPG | 376 | Q9Y6W3 | |
| METGFPAIMYPGSFI | 1 | P78396 | |
| SQGLIPFYMGFIPAM | 276 | Q6J272 | |
| PYEIGMAKYGTFMAP | 351 | P47712 | |
| GSMMCYSILGPFFPK | 46 | Q6NT16 | |
| GELMRGYMTQFPTFP | 946 | P35251 | |
| MFKTFIGPGGNMPGY | 281 | P41250 | |
| VTGVGFYMPMGRIKG | 226 | Q8NEG4 | |
| TKAFPGMLPMGMYGA | 286 | Q9UPG8 | |
| MPAGYFMPIFILGAA | 421 | P51800 | |
| AGFFTPGSMMVGIYG | 216 | Q9P1P5 | |
| MSGFYGKGPSIKQFM | 171 | Q9H857 | |
| FEPGGSMQQGMYTPK | 841 | Q6ZT12 | |
| YFVMEIFATMPGLPG | 321 | Q1EHB4 | |
| GIMMFDGPFQPFYDP | 241 | Q5T124 |